加速超分割放疗联合EP化疗方案治疗局限期小细胞肺癌临床效果.docVIP

加速超分割放疗联合EP化疗方案治疗局限期小细胞肺癌临床效果 　　[摘要]目的 探讨加速超分割放疗联合EP化疗方案治疗局限期小细胞肺癌（LS-SCLC）的临床效果。方法 选取2014年1～12月我院收治的50例LS-SCLC患者作为研究对象，采用随机数字表法将其分为观察组与对照组，每组各25例。对照组患者采用常规三维适型放疗联合标准EP化疗方案治疗，观察组患者采用调强放疗联合标准EP化疗方案治疗。治疗结束2个月后，比较两组患者的治疗总有效率、无进展生存时间、总生存时间、2年生存率及安全性。结果 观察组患者的治疗总有效率明显高于对照组，差异有统计学意义（P0.05）。结论 LS-SCLC采用加速超分割放疗联合EP化疗方案治疗可提高近期疗效，延长患者生存时间，且不会增加毒副作用，是一种安全高效的治疗方案。 　　[关键词]超分割调强放疗；局限期小细胞肺癌；EP方案 　　[中图分类号] R730 [文献标识码] A [文章编号] 1674-4721（2017）12（b）-0047-03 　　[Abstract]Objective To investigate the clinical effect of hypedractionated accelerated radiotherapy （HART） combined with EP chemotherapy regimen in treatment of limited-stage small cell lung cancer （LS-SCLC）.Methods 50 patients of LS-SCLC treated in our hospital from January to December 2014 were selected as subjects，and they were divided into observation group and control group by random number table method，with 25 cases in each group.Control group was given three dimensional conformal radiation therapy and standard EP chemotherapy regimen，while observation group was given intensity modulated radiation therapy and standard EP chemotherapy regimen.After treatment for two months，the total treatment effective rate，progression-free survival，overall survival，two-year survival rate and safety were compared between the two groups.Results The total treatment effective rate of observation group was higher than that of control group，and the difference was statistically significant （P0.05）.Conclusion HART combined with EP chemotherapy regimen in treatment of LS-SCLC can increase short-term efficacy，prolong survival time of patients and not add toxic-side effects，which is a safe and efficient treatment regimen. 　　[Key words]Hyperfractionated intensity modulated radiation therapy；Limited-stage small cell lung cancer；EP regimen 　　肺癌的发病率与死亡率均居所有恶性肿瘤的首位，小细胞肺癌为肺癌的一种常见类型，占肺癌总发生率的15%～20%，而小细胞肺癌中约40%的患者属于局限期，具有易复发、易转移、增殖速度快、预后不佳等特点，对患者的生命安全造成极大的威胁[1-2]。目前临床治疗局限期小细胞肺癌（limited-stage small cell lung cancer，LS-SCLC）的标准疗法为胸腔放疗联合EP化疗方案，LS-SCLC对放